Antiviral Drugs for Treatment of Human Monkeypox: A Systematic Review/Meta-analysis
DOI:
https://doi.org/10.54034/mic.e1963Keywords:
monkeypox, tecovirimat, cidofovir, brincidofovir, meta-analysis, systematicAbstract
Background. On 23 July 2022, the World Health Organization declared a Public Health Emergency of International Concern. Monkeypox is a zoonotic viral disease caused by the monkeypox virus that is transmitted from animals to humans or from human to human. To date, treatment for human monkeypox is mostly symptomatic, as there is no specific standard antiviral treatment. Persons with severe symptoms and signs, immunocompromised patients, children younger than 8 years, and pregnant individuals should be considered for specific antiviral treatment. Objective. This study aims to assess effectiveness of antiviral drugs in treatment of human monkeypox. Methodology. Published clinical trials and cohort studies on the role of antivirals in the management of human monkeypox that were identified through a comprehensive search of electronic databases up to April 1, 2023. The patients included were children and adults confirmed with monkeypox. The diagnosis was based on PCR or clinical symptoms. The intervention was antivirals administration in human monkeypox patients, versus supportive treatment/placebo. Outcome measured include the duration of monkeypox until recovery, need for hospitalization, and ICU admission. Results. We included four completed studies with 195 participants assessing the safety, pharmacokinetics, and efficacy of antiviral treatments for human monkeypox compared to placebo. Three studies investigated Tecovirimat (st-246), and one investigated Brincidofovir. Both drugs were safe, tolerable, and effective with no serious adverse effects. The other 5 studies were not completed and are ongoing. Conclusion. There are currently no approved antivirals for the treatment of monkeypox; some medications could be authorized for outbreak use and are now under investigation, such as Tecovirimat, Cidofovir, and Brincidofovir.
References
Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis 2022;16(2):e0010141.
CDC. Centers for Disease Control and Prevention. 2023 [cited 2024 Mar 1]. Mpox in the U.S. Available from: https://www.cdc.gov/poxvirus/mpox/symptoms/index.html
Mpox (monkeypox) [Internet]. [cited 2024 Mar 1]. Available from: https://www.who.int/news-room/questions-and-answers/item/monkeypox
Commissioner O of the. FDA. FDA; 2020 [cited 2024 Mar 1]. FDA approves the first drug with an indication for treatment of smallpox. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox
Grosenbach DW, Jordan R, Hruby DE. Development of the small-molecule antiviral ST-246® as a smallpox therapeutic. Future Virol 2011;6(5):653–71.
Tecovirimat SIGA | European Medicines Agency [Internet]. [cited 2024 Mar 1]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat-siga
Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther 2021;19(3):331–44.
Mazurkov OY, Kabanov AS, Shishkina LN, Sergeev AA, Skarnovich MO, Bormotov NI, et al. New effective chemically synthesized anti-smallpox compound NIOCH-14. J Gen Virol. 2016;97(5):1229–39.
FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration. J Int Assoc Physicians AIDS Care 1996;2(8):30.
Treatment Information for Healthcare Professionals | Mpox | Poxvirus | CDC [Internet]. 2023 [cited 2024 Mar 3]. Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/treatment.html
Lea AP, Bryson HM. Cidofovir. Drugs 1996;52(2):225–30; discussion 231.
Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997;126(4):257–63.
Research C for DE and. FDA approves drug to treat smallpox. FDA [Internet]. 2021 Sep 30 [cited 2024 Mar 1]; Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox
Chan-Tack K, Harrington P, Bensman T, Choi SY, Donaldson E, O'Rear J, et al. Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation. Antiviral Res 2021;195:105182.
Hutson CL, Kondas AV, Mauldin MR, Doty JB, Grossi IM, Morgan CN, et al. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. mSphere 2021;6(1):e00927-20.
McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014;58(2):260–7.
Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022;22(8):1153–62.
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med 2018;379(1):44–53.
Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, et al. ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. Antimicrob Agents Chemother 2009;53(5):1817–22.
Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother 2012;56(9):4900–5.
Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, et al. Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother 2012;56(7):3582–6.
Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J, et al. Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor. Antimicrob Agents Chemother 2008;52(5):1721–7.
Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. Antiviral Res 2017;143:269–77.
Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012;56(5):2726–34.
Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J Eur Acad Dermatol Venereol 2000;14(6):484–8.
Mazurkov OY, Shishkina LN, Bormotov NI, Skarnovich MO, Serova OA, Mazurkova NA, et al. Estimation of Absolute Bioavailability of the Chemical Substance of the Anti-Smallpox Preparation NIOCH-14 in Mice. Bull Exp Biol Med 2020;170(2):207–10.
Titova KA, Sergeev AA, Zamedyanskaya AS, Galahova DO, Kabanov AS, Morozova AA, et al. Using ICR and SCID mice as animal models for smallpox to assess antiviral drug efficacy. J Gen Virol 2015;96(9):2832–43.
Sergeev AA, Kabanov AS, Bulychev LE, Sergeev AA, Pyankov OV, Bodnev SA, et al. The Possibility of Using the ICR Mouse as an Animal Model to Assess Antimonkeypox Drug Efficacy. Transbound Emerg Dis 2016;63(5):e419-430.
Kabanov AS, Sergeev AA, Shishkina LN, Bulychev LE, Skarnovich MO, Sergeev AA, et al. [A comparative study of the antiviral activity of chemical compounds concerning the orthopoxviruses experiments in vivo]. Vopr Virusol 2013;58(4):39–43.
Alexandra C. A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease [Internet]. clinicaltrials.gov; 2023 Oct [cited 2024 Jan 1]. Report No.: NCT05597735. Available from: https://clinicaltrials.gov/study/NCT05597735
National Institute of Allergy and Infectious Diseases (NIAID). A Randomized, Placebo-controlled, Double-blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Adult and Pediatric Patients With Monkeypox Virus Disease [Internet]. clinicaltrials.gov; 2024 Feb [cited 2024 Jan 1]. Report No.: NCT05559099. Available from: https://clinicaltrials.gov/study/NCT05559099
National Institute of Allergy and Infectious Diseases (NIAID). A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease [Internet]. clinicaltrials.gov; 2024 Feb [cited 2024 Jan 1]. Report No.: NCT05534984. Available from: https://clinicaltrials.gov/study/NCT05534984
ISRCTN - ISRCTN17461766: Antiviral treatment with tecovirimat for patients managed at home with mpox [Internet]. [cited 2024 Mar 3]. Available from: https://www.isrctn.com/ISRCTN17461766
Klein M. Placebo-controlled Randomized Trial of Tecovirimat in Non-hospitalized Patients With Monkeypox: Canadian Feasibility Study (PLATINUM-CAN) [Internet]. clinicaltrials.gov; 2024 Feb [cited 2024 Jan 1]. Report No.: NCT05534165. Available from: https://clinicaltrials.gov/study/NCT05534165
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ahmed Mohamed Abdelghany , Fathy Fathy Ghaly, Mohamed Farouk Allam
This work is licensed under a Creative Commons Attribution 4.0 International License.